Physician profile
Parul Pal
NPI 1487699625
$1,545.96
in general payments reported to CMS, 2019-2025
22 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $33.81 · 2020: $112 · 2021: $282 · 2022: $245 · 2023: $203 · 2024: $171 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $811 · Education: $61.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $811.48 |
| Education | $61.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $377.78 | 2022-2025 | |
| Bausch & Lomb Americas INC. | $182.50 | 2022-2025 | Xiidra, Vyzulta, Doctors Allergy Formula |
| Aerie Pharmaceuticals, INC. | $173.02 | 2021 | |
| Merck Sharp & Dohme LLC | $94.28 | 2022-2024 | Verquvo |
| Oyster Point Pharma, INC. | $91.36 | 2023-2025 | Tyrvaya |
| Sun Pharmaceutical Industries INC. | $86.48 | 2021-2025 | Cequa |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $61.87 | 2019-2021 | |
| Bard Peripheral Vascular, INC. | $51.48 | 2020 | |
| Allergan, INC. | $45.87 | 2019-2022 | |
| Horizon Therapeutics Plc | $42.23 | 2021-2023 | Tepezza |
| Eyevance Pharmaceuticals LLC | $42.14 | 2020 | |
| Alcon Vision LLC | $37.23 | 2024-2025 | Tryptyr, Rocklatan |
| Lkc Technologies, INC. | $35.95 | 2025 | |
| Thea Pharma INC. | $32.03 | 2023 | Iyuzeh |
| Novo Nordisk INC | $31.69 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biotissue Holdings INC. | $30.43 | 2021-2024 | |
| Kiniksa Pharmaceuticals, Ltd. | $23.38 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $22.88 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $22.74 | 2022 | |
| Dompe US, INC. | $22.66 | 2025 | Oxervate |
| Amgen INC. | $20.23 | 2025 | Tepezza |
| Kala Pharmaceuticals, INC. | $17.73 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Parul Pal listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.